Novavax Gains After U.K. Vaccine Study Fully Enrolled
This article is for subscribers only.
Novavax Inc.’s stock reversed an premarket drop to climb as much as 6.6% following other companies developing Covid-19 vaccines higher after the company said a study in the U.K. reached full enrollment and would have results soon.
A first look at results from that 15,000 person trial are expected in the first quarter. Meanwhile a large-scale study in the U.S. and Mexico was delayed for the second time.